Latest EVH news and sentiment

Evolent Health Q2 Earnings Call Highlights

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, while adjusted EBITDA guidance narrowed to $120 million–$135 million. The May launch of the Highmark partnership drove a 50% sequential increase in Performance Suite revenue to $485 million. Evolent reported encouraging early clinical and provider engagement, though the medical expense ratio rose to 95% due largely to higher reserves tied to the launch. Evolent announced an oncology agreement expected to generate about $300 million in annualized revenue and said AI automation, cost controls and maturing contracts should support 2027 revenue growth above 25% and adjusted EBITDA of at least $150 million at the midpoint. Evolent Health (NYSE:EVH) reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business. Chief Executive Officer Seth Blackley said the results reflected the company's ability to execute in a changing healthcare environment. Evolent raised its full-year revenue guidance to a range of $2.6 billion to $2.7 billion, from a prior range of $2.4 billion to $2.6 billion. It also narrowed adjusted EBITDA guidance to $120 million to $135 million, compared with its previous outlook of $110 million to $140 million. → Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling The company maintained its expectation for a full-year medical expense ratio, or MER, of approximately 93%. Highmark Launch Drives Performance Suite Growth Performance Suite revenue totaled $485 million in the second quarter, rising 50% from the first quarter. Chief Financial Officer Mario Ramos said the increase was driven primarily by higher membership following the Highmark launch on May 1. → 4 Oil and Gas ETF Plays as Prices Stay Sky-High Evolent's MER was 95% during the second quarter, compared with 93% in the first quarter. Ramos said the increase was expected and largely reflected the Highmark launch and its associated higher reserves. The company also continued to see higher acuity among exchange populations, though it said its contracts include protections against changes in prevalence. Blackley said early results from the Highmark program were encouraging, with clinical engagement rates above targets and provider engagement exceeding initial go-live expectations. The company expects greater visibility into claims performance over the next several months. Story Continues → No Hangover: Revisiting Microsoft One Week After Earnings Evolent also said its Aetna partnership, which began earlier in 2026, continued to produce clinical engagement above targets, while initial claims-based performance was in line with expectations. For the second half, Ramos said revenue in both the third and fourth quarters is expected to be meaningfully above the second-quarter level, primarily due to Performance Suite revenue. The third quarter is expected to include a full quarter of Highmark revenue and launches in several markets tied to a previously announced Performance Suite expansion. New Oncology and Cross-Sell Agreements The company announced an oncology Performance Suite agreement with an existing advanced-imaging client. The arrangement is expected to cover roughly 1.5 million Medicare and Medicaid lives across 11 states and is anticipated to launch by December 2026, subject to regulatory approvals. Evolent expects the oncology contract to generate approximately $300 million in annualized revenue. Blackley said the agreement includes the company's enhanced contractual protections used in other recent Performance Suite arrangements. The company also expanded its relatio

Evolent Health Inc (EVH) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Market ...

Evolent Health Inc (EVH) Q2 2025 Earnings Call Highlights: Strong Partnerships and Revenue ...